Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.800
+0.190 (5.26%)
At close: Jun 26, 2026, 4:00 PM EDT
3.730
-0.070 (-1.84%)
After-hours: Jun 26, 2026, 6:57 PM EDT
Fulcrum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
253.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 80.00M | 77.20M | 2,752.05% |
| Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
| Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
| Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Invivyd | 55.87M |
| Orchestra BioMed Holdings | 32.72M |
| Foghorn Therapeutics | 28.22M |
| Sol-Gel Technologies | 18.47M |
| Fate Therapeutics | 6.32M |
| Armata Pharmaceuticals | 5.20M |
| AC Immune | 4.62M |
FULC News
- 26 days ago - Fulcrum Therapeutics downgraded to Underweight from Overweight at JPMorgan - TheFly
- 26 days ago - Goldman suspends rating on Fulcrum Therapeutics - TheFly
- 26 days ago - Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses - GlobeNewsWire
- 26 days ago - Fulcrum Therapeutics price target lowered to $3 from $8 at BofA - TheFly
- 26 days ago - Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns - Reuters
- 26 days ago - Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink - TheFly
- 26 days ago - Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 26 days ago - Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink - TheFly